Amneal Pharmaceuticals, Class Stock Buy Hold or Sell Recommendation
| AMRX Stock | USD 8.38 0.01 0.12% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Amneal Pharmaceuticals, Class is 'Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Amneal Pharmaceuticals, Class given historical horizon and risk tolerance towards Amneal Pharmaceuticals,. When Macroaxis issues a 'buy' or 'sell' recommendation for Amneal Pharmaceuticals, Class, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Amneal Pharmaceuticals, Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Amneal and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Amneal Pharmaceuticals, Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Amneal |
Execute Amneal Pharmaceuticals, Buy or Sell Advice
The Amneal recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Amneal Pharmaceuticals, Class. Macroaxis does not own or have any residual interests in Amneal Pharmaceuticals, Class or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Amneal Pharmaceuticals,'s advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Amneal Pharmaceuticals, Trading Alerts and Improvement Suggestions
| Amneal Pharmaceuticals, generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 2.39 B. Net Loss for the year was (48.72 M) with profit before overhead, payroll, taxes, and interest of 791.46 M. | |
| Amneal Pharmaceuticals, has a strong financial position based on the latest SEC filings | |
| About 53.0% of the company shares are held by company insiders | |
| Latest headline from simplywall.st: Senior VP Of Amneal Pharmaceuticals Sold 76 percent Of Their Shares |
Amneal Pharmaceuticals, Returns Distribution Density
The distribution of Amneal Pharmaceuticals,'s historical returns is an attempt to chart the uncertainty of Amneal Pharmaceuticals,'s future price movements. The chart of the probability distribution of Amneal Pharmaceuticals, daily returns describes the distribution of returns around its average expected value. We use Amneal Pharmaceuticals, Class price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Amneal Pharmaceuticals, returns is essential to provide solid investment advice for Amneal Pharmaceuticals,.
| Mean Return | 0.08 | Value At Risk | -2.38 | Potential Upside | 3.03 | Standard Deviation | 1.82 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Amneal Pharmaceuticals, historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Amneal Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Amneal Pharmaceuticals,, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Amneal Pharmaceuticals, Class back and forth among themselves.
| Shares | Nuveen Asset Management, Llc | 2024-06-30 | 2.5 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.1 M | Blackbarn Capital Partners Lp | 2024-06-30 | 2 M | Fosun International Ltd | 2024-09-30 | 1.7 M | Northern Trust Corp | 2024-09-30 | 1.6 M | Hennessy Advisors, Inc. | 2024-09-30 | 1.6 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.4 M | Goldman Sachs Group Inc | 2024-06-30 | 1.4 M | Woodline Partners Lp | 2024-06-30 | 1.3 M | Ubs Group Ag | 2024-06-30 | 21.8 M | Vanguard Group Inc | 2024-09-30 | 14.6 M |
Amneal Pharmaceuticals, Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (20.4M) | (113.8M) | (49.0M) | (102.4M) | (126.2M) | (119.9M) | |
| Change In Cash | (66.0M) | 194.3M | (90.4M) | (221.5M) | 63.9M | 67.1M | |
| Net Borrowings | (27M) | 175.9M | (1M) | 83.3M | 75.0M | 71.3M | |
| Free Cash Flow | (95.7M) | 312.8M | 189.2M | (25.5M) | 276.4M | 290.2M | |
| Depreciation | 207.2M | 235.4M | 233.4M | 240.2M | 229.4M | 154.9M | |
| Other Non Cash Items | 124.9M | 20.0M | 10.0M | 107.8M | 185.3M | 194.5M | |
| Dividends Paid | 375.3M | 183.0M | 0.0 | 3.6M | 3.2M | 3.1M | |
| Capital Expenditures | 97.4M | 66.2M | 52.6M | 90.6M | 69.2M | 72.7M | |
| Net Income | (603.6M) | 68.6M | 20.2M | (254.8M) | (48.7M) | (46.3M) | |
| End Period Cash Flow | 152.8M | 347.1M | 256.7M | 35.2M | 99.1M | 154.4M | |
| Change To Netincome | 655.8M | 128.2M | 112.5M | 132.1M | 151.9M | 170.7M | |
| Investments | (19.6M) | (317.5M) | (194.2M) | (174.3M) | (69.2M) | (72.6M) | |
| Change Receivables | (133.7M) | 17.2M | (16.3M) | (80.1M) | (72.1M) | (68.5M) |
Amneal Pharmaceuticals, Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Amneal Pharmaceuticals, or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Amneal Pharmaceuticals,'s price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Amneal stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.05 | |
β | Beta against Dow Jones | 0.95 | |
σ | Overall volatility | 1.77 | |
Ir | Information ratio | -0.03 |
Amneal Pharmaceuticals, Volatility Alert
Amneal Pharmaceuticals, Class has relatively low volatility with skewness of 0.09 and kurtosis of 1.75. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Amneal Pharmaceuticals,'s stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Amneal Pharmaceuticals,'s stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Amneal Pharmaceuticals, Fundamentals Vs Peers
Comparing Amneal Pharmaceuticals,'s fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Amneal Pharmaceuticals,'s direct or indirect competition across all of the common fundamentals between Amneal Pharmaceuticals, and the related equities. This way, we can detect undervalued stocks with similar characteristics as Amneal Pharmaceuticals, or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Amneal Pharmaceuticals,'s fundamental indicators could also be used in its relative valuation, which is a method of valuing Amneal Pharmaceuticals, by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Amneal Pharmaceuticals, to competition |
| Fundamentals | Amneal Pharmaceuticals, | Peer Average |
| Return On Equity | -1.86 | -0.31 |
| Return On Asset | 0.0594 | -0.14 |
| Profit Margin | (0.07) % | (1.27) % |
| Operating Margin | 0.12 % | (5.51) % |
| Current Valuation | 5.17 B | 16.62 B |
| Shares Outstanding | 309.84 M | 571.82 M |
| Shares Owned By Insiders | 53.34 % | 10.09 % |
| Shares Owned By Institutions | 46.26 % | 39.21 % |
| Number Of Shares Shorted | 3.5 M | 4.71 M |
| Price To Earning | 230.50 X | 28.72 X |
| Price To Book | 86.10 X | 9.51 X |
| Price To Sales | 1.45 X | 11.42 X |
| Revenue | 2.39 B | 9.43 B |
| Gross Profit | 791.46 M | 27.38 B |
| EBITDA | 500.78 M | 3.9 B |
| Net Income | (48.72 M) | 570.98 M |
| Cash And Equivalents | 87.33 M | 2.7 B |
| Cash Per Share | 0.58 X | 5.01 X |
| Total Debt | 2.75 B | 5.32 B |
| Current Ratio | 1.74 X | 2.16 X |
| Book Value Per Share | (0.30) X | 1.93 K |
| Cash Flow From Operations | 345.58 M | 971.22 M |
| Short Ratio | 4.23 X | 4.00 X |
| Earnings Per Share | (0.86) X | 3.12 X |
| Price To Earnings To Growth | (0.30) X | 4.89 X |
| Target Price | 10.5 | |
| Number Of Employees | 7.85 K | 18.84 K |
| Beta | 1.18 | -0.15 |
| Market Capitalization | 3.88 B | 19.03 B |
| Total Asset | 3.47 B | 29.47 B |
| Retained Earnings | (490.18 M) | 9.33 B |
| Working Capital | 531.27 M | 1.48 B |
| Current Asset | 753.39 M | 9.34 B |
Note: Disposition of 76453 shares by Jeffrey George of Amneal Pharmaceuticals, subject to Rule 16b-3 [view details]
Amneal Pharmaceuticals, Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Amneal . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Amneal Pharmaceuticals, Buy or Sell Advice
When is the right time to buy or sell Amneal Pharmaceuticals, Class? Buying financial instruments such as Amneal Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Amneal Pharmaceuticals, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Crypto And Gold Thematic Idea Now
Crypto And Gold
Assets that cancel away each other volatility by providing diversification into gold investment combined with digital assets. The Crypto And Gold theme has 54 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Crypto And Gold Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.